|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02616 CSTONE PHARMA-B
Nominal 
6.165 -0.010 (-0.162%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 205,099 | 314.752% | 269,583 | 407,205 | 463,842 | 481,363 |
| Cost of Sales | (110,900) | -22.034% | (218,336) | (167,051) | (159,547) | (202,985) |
| Gross Profit | 94,199 | -- | 51,247 | 240,154 | 304,295 | 278,378 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (252,284) | -6.625% | (423,939) | (91,207) | (367,234) | (902,678) | |
| Taxation | 0 | -- | (13,064) | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (252,284) | -6.625% | (437,003) | (91,207) | (367,234) | (902,678) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (4,255) | -- | 2,885 | 2,500 | (13,067) | (1,195) |
| Depreciation & Amortisation | 22,219 | 0.561% | 43,981 | 49,805 | 58,190 | 44,540 |
| Directors' Emoluments | 15,205 | 39.380% | 26,055 | 31,055 | 59,498 | 83,640 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | -17.000 | -19.048% | -31.000 | -7.000 | -29.000 | -77.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.236) | (0.269) | (0.466) | (0.521) |
| NBV per share ($) | 0.807 | -- | 0.418 | 0.283 | 0.356 | 0.375 |
| Remarks: | Real time quote last updated: 09/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -252,284 |
| %Change | -6.625% |
| EPS / (LPS) | RMB -0.170 |
| NBV Per Share (¥) | RMB 0.807 |